Cureline

Executive Summary

Cureline is a US-based contract research organization (CRO) and global biobank founded in 2003, specializing in the procurement, management, and analysis of human biospecimens (HBS). The company provides critical services and materials to accelerate drug discovery, biomarker research, and diagnostic development, primarily in oncology and other therapeutic areas. Its offerings include a biorepository of annotated tissues, primary cells, and biofluids, coupled with integrated laboratory and consulting services. By enabling pharmaceutical and biotechnology firms to access high-quality, well-characterized biospecimens, Cureline plays a pivotal role in advancing precision medicine and reducing the time and cost of bringing new therapies to market. Cureline's expertise in biospecimen science positions it as a key partner in the drug development ecosystem. As the demand for translational research and biomarker-driven clinical trials grows, the company is well-placed to expand its service offerings and geographic reach. With a focus on oncology and a track record of supporting hundreds of clients, Cureline continues to invest in its biorepository infrastructure and analytical capabilities. The company's long-standing presence since 2003 underscores its reliability and deep domain knowledge, making it a trusted partner for both small biotechs and large pharmaceutical companies.

Upcoming Catalysts (preview)

• Q4 2026Expansion of biorepository capacity with new tissue collection sites70% success
• Q2 2027Strategic partnership with a top-20 pharmaceutical company for oncology biomarker services40% success
• Q3 2027Launch of a novel liquid biopsy service for early cancer detection50% success